64 results
Page 2 of 4
424B5
e56jah 0wzko4g1
12 Aug 22
Prospectus supplement for primary offering
1:32pm
6-K
EX-99.1
s8nji1id
12 Aug 22
Silence Therapeutics Announces Pricing of Underwritten Offering
6:07am
6-K
EX-99.1
iefewkt0
11 Aug 22
6-K Q2 2022 Quarterly Results
5:02pm
6-K
EX-99.1
17y2 0acjwizu83g
16 May 22
Current report (foreign)
8:31am
6-K
EX-99.1
lohxts82jm784265c5
25 Apr 22
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration
8:31am
6-K
EX-99.1
cc0vpyg s9
4 Apr 22
Current report (foreign)
8:31am
6-K
EX-99.1
v7fy8 vla4d
23 Mar 22
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
8:30am
6-K
EX-99.1
gec3ocfn
22 Feb 22
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
6:52am
6-K
EX-99.1
7p1cf48iu0tfxg
9 Feb 22
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study
7:30am
6-K
EX-99.1
j4o327gi b3dl
13 Dec 21
Current report (foreign)
6:01am
6-K
EX-99.1
8qcm 575c
16 Nov 21
Current report (foreign)
6:03am
424B5
5wbztrkm5k22664353ig
22 Oct 21
Prospectus supplement for primary offering
4:34pm
6-K
EX-99.1
yh7omh
21 Oct 21
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
8:45am
F-3
rr9uvpau
15 Oct 21
Shelf registration (foreign)
7:41am
F-3
EX-1.1
xn9wba
15 Oct 21
Shelf registration (foreign)
7:41am
6-K/A
EX-99.1
ol9zo6qm
15 Oct 21
Current report (foreign) (amended)
7:19am
6-K
EX-99.2
dt4 q9gjub
15 Oct 21
Notice of General Meeting to be held on 1Â November 2021
7:15am
6-K
EX-99.1
9m2d8
12 Aug 21
Current report (foreign)
4:38pm